IOVANCE BIOTHERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $2.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $902.00K, a 68.65% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $1.88M, a 34.63% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $2.72M, a 14.21% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $2.92M, a 13.17% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $11.38M, a 9.08% increase from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $10.44M, a 10.87% decline from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $11.71M, a 0.97% decline from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $11.82M, a 8.80% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $902.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.78M 10-Q · filed 2026-08-06 | $5.49M derived: sum of 3 quarters · filed 2026-08-06 | $8.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.88M 10-Q · filed 2026-05-07 | $4.59M derived: sum of 2 quarters · filed 2026-05-07 | $7.51M derived: sum of 3 quarters · filed 2026-05-07 | $10.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $5.64M derived: sum of 2 quarters · filed 2026-02-24 | $8.52M derived: sum of 3 quarters · filed 2026-08-06 | $11.38M 10-K · filed 2026-02-24 |
| 2025-09-30 | $2.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.80M derived: sum of 2 quarters · filed 2026-08-06 | $8.67M 10-Q · filed 2025-11-06 | $11.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.75M 10-Q · filed 2026-08-06 | $8.91M derived: sum of 3 quarters · filed 2026-08-06 | $11.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.87M 10-Q · filed 2026-05-07 | $6.04M derived: sum of 2 quarters · filed 2026-05-07 | $8.62M derived: sum of 3 quarters · filed 2026-05-07 | $11.01M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $5.75M derived: sum of 2 quarters · filed 2026-02-24 | $8.14M derived: sum of 3 quarters · filed 2026-02-24 | $10.44M 10-K · filed 2026-02-24 |
| 2024-09-30 | $2.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.97M derived: sum of 2 quarters · filed 2025-11-06 | $7.27M 10-Q · filed 2025-11-06 | $10.13M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $2.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.69M 10-Q · filed 2025-08-07 | $7.54M derived: sum of 3 quarters · filed 2026-02-24 | $10.49M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $2.30M 10-Q · filed 2025-05-08 | $5.15M derived: sum of 2 quarters · filed 2026-02-24 | $8.10M derived: sum of 3 quarters · filed 2026-02-24 | $11.07M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $5.80M derived: sum of 2 quarters · filed 2026-02-24 | $8.78M derived: sum of 3 quarters · filed 2026-02-24 | $11.71M 10-K · filed 2026-02-24 |
| 2023-09-30 | $2.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.92M derived: sum of 2 quarters · filed 2024-11-07 | $8.86M 10-Q · filed 2024-11-07 | $11.75M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.91M 10-Q · filed 2024-08-08 | $8.80M derived: sum of 3 quarters · filed 2025-02-27 | $11.55M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.93M 10-Q · filed 2024-05-09 | $5.83M derived: sum of 2 quarters · filed 2025-02-27 | $8.57M derived: sum of 3 quarters · filed 2025-02-27 | $11.58M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $5.64M derived: sum of 2 quarters · filed 2025-02-27 | $8.64M derived: sum of 3 quarters · filed 2025-02-27 | $11.82M 10-K · filed 2025-02-27 |
| 2022-09-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $5.75M derived: sum of 2 quarters · filed 2023-11-07 | $8.93M 10-Q · filed 2023-11-07 | $12.05M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $6.18M 10-Q · filed 2023-08-08 | $9.30M derived: sum of 3 quarters · filed 2024-02-28 | $12.24M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $3.18M 10-Q · filed 2023-05-10 | $6.30M derived: sum of 2 quarters · filed 2024-02-28 | $9.24M derived: sum of 3 quarters · filed 2024-02-28 | $11.65M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $6.06M derived: sum of 2 quarters · filed 2024-02-28 | $8.47M derived: sum of 3 quarters · filed 2024-02-28 | $10.87M 10-K · filed 2024-02-28 |
| 2021-09-30 | $2.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $5.35M derived: sum of 2 quarters · filed 2022-11-03 | $7.75M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $2.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $4.81M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $2.40M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $7.57M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $6.95M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |